Is there a place for Ramucirumab after Sorafenib in patients with advanced HCC?

Yeo Jeong So, Sophia Frentzas, Eva Segelov

Research output: Contribution to journalComment / DebateOtherpeer-review


Hepatocellular carcinoma (HCC) is the sixth most common incident and the fourth most common cause of cancer death worldwide. It is strongly associated with chronic Hepatitis B and C infection and excess alcohol intake (1), making treatment of patients with HCC complicated, with the almost uniform presence of concurrent cirrhosis and varying degrees of liver failure, which often fluctuates over time.
Original languageEnglish
Pages (from-to)546-548
Number of pages3
JournalHepatobiliary Surgery and Nutrition
Issue number5
Publication statusPublished - Oct 2019

Cite this